Amanjot Gill, MD
Psychiatry · Sacramento, CANPI 1336401041
Payments from drug & device makers
Across 46 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$219
- Otsuka America Pharmaceutical, Inc.$115
- Neurocrine Biosciences, Inc.$108
- Bausch Health US, LLC$57
- Takeda Pharmaceuticals U.S.A., Inc.$51
- Johnson & Johnson$36
- plus $114 from 5 others
What the payments were for
- Food & beverage$700100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $219 |
| Otsuka America Pharmaceutical, Inc. | 8 | $115 |
| Neurocrine Biosciences, Inc. | 4 | $108 |
| Bausch Health US, LLC | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $51 |
| Johnson & Johnson | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| Adlon Therapeutics L.p. | 1 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Lundbeck LLC | 1 | $14 |
How this compares
$700 in reported general payments places this provider in the 70th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 66 | $5,757 |
| Lisdexamfetamine Dimesylate | 14 | $2,987 |
| Lurasidone Hcl | 15 | $1,790 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 19 | $1,240 |
| Quetiapine Fumarate | 37 | $1,070 |
| Bupropion XlBupropion Hcl | 52 | $1,044 |
| Vilazodone Hcl | 15 | $662 |
| Lamotrigine | 67 | $601 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 34 | $534 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 28 | $528 |
| Fluoxetine Hcl | 49 | $515 |
| Sertraline Hcl | 53 | $512 |
| Bupropion Hcl SrBupropion Hcl | 30 | $446 |
| Oxcarbazepine | 14 | $386 |
| Buspirone Hcl | 19 | $386 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Sacramento
- Susan SmigaSacramento$1.7M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.